The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Anti-thrombotic therapy is crucial after heart valve replacement, with different strategies for mechanical and bioprosthetic valves.
• Current guidelines present some discrepancies and rely on low levels of evidence for specific recommendations.

Purpose of the Study:

• To review and summarize current anti-thrombotic therapy strategies following mechanical and bioprosthetic heart valve replacement.
• To identify areas where further research and controlled trials are needed to optimize patient outcomes.

Main Methods:

• Review of current international guidelines and existing literature on anti-thrombotic therapy post-valve replacement.
• Analysis of treatment protocols for mechanical prostheses (e.g., vitamin K antagonists, aspirin) and bioprostheses (e.g., anticoagulation, aspirin).
• Examination of emerging therapies like direct oral anticoagulants and dual antiplatelet therapy after transcatheter aortic valve implantation.

Main Results:

• Mechanical valves typically require long-term anticoagulation with vitamin K antagonists, with aspirin use varying by guideline.
• Bioprosthetic valves generally avoid long-term anticoagulation, with early aspirin favored for aortic position and anticoagulation for mitral position.
• Transcatheter aortic valve implantation (TAVI) involves dual antiplatelet therapy followed by single therapy, though evidence is limited.

Conclusions:

• Optimization of anti-thrombotic therapy is warranted, particularly for high-risk patients undergoing TAVI.
• Further controlled trials are essential to clarify optimal timing, type, and dosage of anti-thrombotic agents, especially concerning combined therapies and early post-operative management.